Morie A. Gertz, MD - Don’t Miss the Rare When Diagnosing and Treating Autoimmune Hemolytic Anemia: Focus on CAD

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/MVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies that target the classical complement pathway and individualizing treatment plans for patients living with CAD. Upon completion of this activity, participants should be better able to: Describe the consequences of inhibiting complement C1s as long-term therapy for CAD, particularly on symptoms influenced predominantly by activation of the classical complement pathway (eg, chronic hemolysis, anemia, and fatigue); and Integrate classical complement pathway–targeted therapies into individualized treatment plans for CAD based on consideration of efficacy and safety data, patient-specific characteristics, and other potential prescribing considerations.